KR20180019536A - 신규한 백금(ⅳ) 착물 - Google Patents
신규한 백금(ⅳ) 착물 Download PDFInfo
- Publication number
- KR20180019536A KR20180019536A KR1020177034814A KR20177034814A KR20180019536A KR 20180019536 A KR20180019536 A KR 20180019536A KR 1020177034814 A KR1020177034814 A KR 1020177034814A KR 20177034814 A KR20177034814 A KR 20177034814A KR 20180019536 A KR20180019536 A KR 20180019536A
- Authority
- KR
- South Korea
- Prior art keywords
- platinum
- complex
- compound
- cis
- dach
- Prior art date
Links
- NDBYXKQCPYUOMI-UHFFFAOYSA-N platinum(4+) Chemical compound [Pt+4] NDBYXKQCPYUOMI-UHFFFAOYSA-N 0.000 title claims abstract description 36
- 125000005843 halogen group Chemical group 0.000 claims abstract description 18
- 239000003814 drug Substances 0.000 claims abstract description 11
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 claims abstract description 7
- OFOBLEOULBTSOW-UHFFFAOYSA-L Malonate Chemical compound [O-]C(=O)CC([O-])=O OFOBLEOULBTSOW-UHFFFAOYSA-L 0.000 claims abstract description 4
- KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 claims abstract description 4
- 239000003446 ligand Substances 0.000 claims description 15
- 125000001309 chloro group Chemical group Cl* 0.000 claims description 10
- 239000004480 active ingredient Substances 0.000 claims description 4
- SSJXIUAHEKJCMH-UHFFFAOYSA-N cyclohexane-1,2-diamine Chemical compound NC1CCCCC1N SSJXIUAHEKJCMH-UHFFFAOYSA-N 0.000 claims description 4
- SSJXIUAHEKJCMH-PHDIDXHHSA-N (1r,2r)-cyclohexane-1,2-diamine Chemical compound N[C@@H]1CCCC[C@H]1N SSJXIUAHEKJCMH-PHDIDXHHSA-N 0.000 claims description 2
- 125000001246 bromo group Chemical group Br* 0.000 claims 1
- 150000003891 oxalate salts Chemical class 0.000 claims 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 abstract description 23
- 229940079593 drug Drugs 0.000 abstract description 8
- 230000000259 anti-tumor effect Effects 0.000 abstract description 7
- 150000007942 carboxylates Chemical class 0.000 abstract description 3
- 150000001875 compounds Chemical class 0.000 description 52
- 230000000052 comparative effect Effects 0.000 description 20
- 239000007787 solid Substances 0.000 description 16
- BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Substances [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 description 12
- 238000004458 analytical method Methods 0.000 description 11
- 238000006243 chemical reaction Methods 0.000 description 11
- 239000012153 distilled water Substances 0.000 description 11
- 239000000203 mixture Substances 0.000 description 11
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 10
- 238000004128 high performance liquid chromatography Methods 0.000 description 10
- 239000000243 solution Substances 0.000 description 10
- 238000012360 testing method Methods 0.000 description 10
- 238000005160 1H NMR spectroscopy Methods 0.000 description 9
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 9
- 229910052801 chlorine Inorganic materials 0.000 description 8
- 101100498160 Mus musculus Dach1 gene Proteins 0.000 description 7
- 230000015572 biosynthetic process Effects 0.000 description 7
- 238000003786 synthesis reaction Methods 0.000 description 7
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 6
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical group [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 6
- MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 6
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 6
- JRNVZBWKYDBUCA-UHFFFAOYSA-N N-chlorosuccinimide Chemical compound ClN1C(=O)CCC1=O JRNVZBWKYDBUCA-UHFFFAOYSA-N 0.000 description 6
- 238000000132 electrospray ionisation Methods 0.000 description 6
- 206010061902 Pancreatic neoplasm Diseases 0.000 description 5
- 208000005718 Stomach Neoplasms Diseases 0.000 description 5
- 238000002835 absorbance Methods 0.000 description 5
- 239000007864 aqueous solution Substances 0.000 description 5
- 239000000460 chlorine Substances 0.000 description 5
- 230000000694 effects Effects 0.000 description 5
- 206010017758 gastric cancer Diseases 0.000 description 5
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 5
- 230000002401 inhibitory effect Effects 0.000 description 5
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 description 5
- 201000002528 pancreatic cancer Diseases 0.000 description 5
- 208000008443 pancreatic carcinoma Diseases 0.000 description 5
- 239000002504 physiological saline solution Substances 0.000 description 5
- HRGDZIGMBDGFTC-UHFFFAOYSA-N platinum(2+) Chemical compound [Pt+2] HRGDZIGMBDGFTC-UHFFFAOYSA-N 0.000 description 5
- 201000011549 stomach cancer Diseases 0.000 description 5
- 230000004663 cell proliferation Effects 0.000 description 4
- DQLATGHUWYMOKM-UHFFFAOYSA-L cisplatin Chemical compound N[Pt](N)(Cl)Cl DQLATGHUWYMOKM-UHFFFAOYSA-L 0.000 description 4
- 229960004316 cisplatin Drugs 0.000 description 4
- 239000000706 filtrate Substances 0.000 description 4
- 238000000034 method Methods 0.000 description 4
- 229960001756 oxaliplatin Drugs 0.000 description 4
- DWAFYCQODLXJNR-BNTLRKBRSA-L oxaliplatin Chemical compound O1C(=O)C(=O)O[Pt]11N[C@@H]2CCCC[C@H]2N1 DWAFYCQODLXJNR-BNTLRKBRSA-L 0.000 description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 3
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 3
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 3
- 239000002246 antineoplastic agent Substances 0.000 description 3
- 238000001914 filtration Methods 0.000 description 3
- 239000011541 reaction mixture Substances 0.000 description 3
- 238000013112 stability test Methods 0.000 description 3
- -1 that is Chemical compound 0.000 description 3
- RBTBFTRPCNLSDE-UHFFFAOYSA-N 3,7-bis(dimethylamino)phenothiazin-5-ium Chemical compound C1=CC(N(C)C)=CC2=[S+]C3=CC(N(C)C)=CC=C3N=C21 RBTBFTRPCNLSDE-UHFFFAOYSA-N 0.000 description 2
- XMIIGOLPHOKFCH-UHFFFAOYSA-N 3-phenylpropionic acid Chemical compound OC(=O)CCC1=CC=CC=C1 XMIIGOLPHOKFCH-UHFFFAOYSA-N 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- PCLIMKBDDGJMGD-UHFFFAOYSA-N N-bromosuccinimide Chemical compound BrN1C(=O)CCC1=O PCLIMKBDDGJMGD-UHFFFAOYSA-N 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 2
- 230000001093 anti-cancer Effects 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 238000002512 chemotherapy Methods 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- 229960000907 methylthioninium chloride Drugs 0.000 description 2
- 229910052697 platinum Inorganic materials 0.000 description 2
- 238000012552 review Methods 0.000 description 2
- 238000001228 spectrum Methods 0.000 description 2
- 239000012192 staining solution Substances 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 description 1
- BDNKZNFMNDZQMI-UHFFFAOYSA-N 1,3-diisopropylcarbodiimide Chemical compound CC(C)N=C=NC(C)C BDNKZNFMNDZQMI-UHFFFAOYSA-N 0.000 description 1
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical group [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 1
- 125000000041 C6-C10 aryl group Chemical group 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
- 206010009944 Colon cancer Diseases 0.000 description 1
- 208000001333 Colorectal Neoplasms Diseases 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 206010034133 Pathogen resistance Diseases 0.000 description 1
- 208000001647 Renal Insufficiency Diseases 0.000 description 1
- 206010047700 Vomiting Diseases 0.000 description 1
- DHPOXNUQQATQBK-UHFFFAOYSA-N [Pt+4].[Pt+4] Chemical compound [Pt+4].[Pt+4] DHPOXNUQQATQBK-UHFFFAOYSA-N 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 150000001412 amines Chemical group 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000002648 combination therapy Methods 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- CCQPAEQGAVNNIA-UHFFFAOYSA-N cyclobutane-1,1-dicarboxylic acid Chemical compound OC(=O)C1(C(O)=O)CCC1 CCQPAEQGAVNNIA-UHFFFAOYSA-N 0.000 description 1
- 238000000354 decomposition reaction Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- BGRWYRAHAFMIBJ-UHFFFAOYSA-N diisopropylcarbodiimide Natural products CC(C)NC(=O)NC(C)C BGRWYRAHAFMIBJ-UHFFFAOYSA-N 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 230000001747 exhibiting effect Effects 0.000 description 1
- 229910052731 fluorine Inorganic materials 0.000 description 1
- 125000001153 fluoro group Chemical group F* 0.000 description 1
- 235000011194 food seasoning agent Nutrition 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 229910052736 halogen Inorganic materials 0.000 description 1
- 150000002367 halogens Chemical class 0.000 description 1
- 229910052739 hydrogen Inorganic materials 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- 125000004435 hydrogen atom Chemical class [H]* 0.000 description 1
- 230000005918 in vitro anti-tumor Effects 0.000 description 1
- 229910052740 iodine Inorganic materials 0.000 description 1
- 201000006370 kidney failure Diseases 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- PSHKMPUSSFXUIA-UHFFFAOYSA-N n,n-dimethylpyridin-2-amine Chemical compound CN(C)C1=CC=CC=N1 PSHKMPUSSFXUIA-UHFFFAOYSA-N 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- 239000007800 oxidant agent Substances 0.000 description 1
- 208000033808 peripheral neuropathy Diseases 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 230000000704 physical effect Effects 0.000 description 1
- 230000001766 physiological effect Effects 0.000 description 1
- 239000000049 pigment Substances 0.000 description 1
- 150000003057 platinum Chemical class 0.000 description 1
- XAEFZNCEHLXOMS-UHFFFAOYSA-M potassium benzoate Chemical compound [K+].[O-]C(=O)C1=CC=CC=C1 XAEFZNCEHLXOMS-UHFFFAOYSA-M 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- ROBLTDOHDSGGDT-UHFFFAOYSA-M sodium;pentane-1-sulfonate Chemical compound [Na+].CCCCCS([O-])(=O)=O ROBLTDOHDSGGDT-UHFFFAOYSA-M 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 125000001424 substituent group Chemical group 0.000 description 1
- 125000005415 substituted alkoxy group Chemical group 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 238000007910 systemic administration Methods 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 230000008685 targeting Effects 0.000 description 1
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F15/00—Compounds containing elements of Groups 8, 9, 10 or 18 of the Periodic Table
- C07F15/0006—Compounds containing elements of Groups 8, 9, 10 or 18 of the Periodic Table compounds of the platinum group
- C07F15/0086—Platinum compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/28—Compounds containing heavy metals
- A61K31/282—Platinum compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C211/00—Compounds containing amino groups bound to a carbon skeleton
- C07C211/65—Metal complexes of amines
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F15/00—Compounds containing elements of Groups 8, 9, 10 or 18 of the Periodic Table
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F15/00—Compounds containing elements of Groups 8, 9, 10 or 18 of the Periodic Table
- C07F15/0006—Compounds containing elements of Groups 8, 9, 10 or 18 of the Periodic Table compounds of the platinum group
- C07F15/0086—Platinum compounds
- C07F15/0093—Platinum compounds without a metal-carbon linkage
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JPJP-P-2015-126116 | 2015-06-24 | ||
| JP2015126116 | 2015-06-24 | ||
| PCT/JP2016/067903 WO2016208481A1 (ja) | 2015-06-24 | 2016-06-16 | 新規白金（ｉｖ）錯体 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| KR20180019536A true KR20180019536A (ko) | 2018-02-26 |
Family
ID=57585438
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020177034814A KR20180019536A (ko) | 2015-06-24 | 2016-06-16 | 신규한 백금(ⅳ) 착물 |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US10988496B2 (zh) |
| EP (1) | EP3315487B1 (zh) |
| JP (1) | JP6797116B2 (zh) |
| KR (1) | KR20180019536A (zh) |
| CN (1) | CN107709286B (zh) |
| AU (1) | AU2016284156B2 (zh) |
| CA (1) | CA2990369A1 (zh) |
| RU (1) | RU2695357C1 (zh) |
| TW (1) | TWI703151B (zh) |
| WO (1) | WO2016208481A1 (zh) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP6725520B2 (ja) | 2015-09-14 | 2020-07-22 | 日本化薬株式会社 | ６配位白金錯体の高分子結合体 |
Family Cites Families (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SU1186617A1 (ru) | 1980-01-03 | 1985-10-23 | Нидерландзе Сентрале Организати Фор Тегепаст-Натурветеншаппелийк Ондерцоек (Фирма) | Платино ( @ )-диаминовые комплексы,про вл ющие противоопухолевую активность |
| NL181434C (nl) | 1980-01-03 | 1987-08-17 | Tno | Platina(iv)-diamine-complexen, alsmede hun bereiding en toepassing. |
| JPS617283A (ja) | 1984-06-20 | 1986-01-13 | Shionogi & Co Ltd | 新規白金錯体および抗悪性腫瘍剤 |
| JPS62207283A (ja) * | 1986-03-07 | 1987-09-11 | Yoshinori Kitani | 新規な白金錯体 |
| DE68918878T2 (de) | 1988-02-02 | 1995-02-23 | Johnson Matthey Inc | Pt(IV) Komplexe. |
| US5072011A (en) | 1988-02-02 | 1991-12-10 | Johnson Matthey, Inc. | Pt(IV) complexes |
| US5434256A (en) * | 1988-11-22 | 1995-07-18 | Board Of Regents, The University Of Texas System | Diamine platinum complexes as antitumor agents |
| US5393909A (en) * | 1988-11-22 | 1995-02-28 | Board Of Regents, The University Of Texas System | Diamine platinum complexes as antitumor agents |
| US5041578A (en) | 1988-11-22 | 1991-08-20 | Board Of Regents, The University Of Texas System | Water soluble 1,2-diaminocyclohexane platinum (IV) complexes as antitumor agents |
| JPH03279392A (ja) | 1990-03-29 | 1991-12-10 | Sankyo Co Ltd | ４価白金錯体 |
| JPH05117385A (ja) | 1991-10-31 | 1993-05-14 | Res Dev Corp Of Japan | ブロツク共重合体の製造法、ブロツク共重合体及び水溶性高分子抗癌剤 |
| JP3268913B2 (ja) | 1992-10-27 | 2002-03-25 | 日本化薬株式会社 | 高分子担体 |
| WO1996026949A1 (fr) | 1995-02-28 | 1996-09-06 | Debiopharm Sa | Nouveaux complexes de platine (iv), leur procede de production et agents cancerostatiques les contenant |
| KR100729015B1 (ko) | 2000-01-04 | 2007-06-14 | 어섹스 팔마큐티칼스 인코포레이티드 | Ｎ,ｏ-아미도말로네이트 백금 착화합물 |
| US7166733B2 (en) | 2000-01-04 | 2007-01-23 | Access Pharmaceuticals, Inc. | O,O'-Amidomalonate and N,O-Amidomalonate platinum complexes |
| CN1681558A (zh) | 2002-09-11 | 2005-10-12 | 得克萨斯州大学系统董事会 | 作为抗肿瘤剂的铂复合物与生物化学调节剂的组合 |
| US7495099B2 (en) | 2002-10-31 | 2009-02-24 | Nippon Kayaku Kabushiki Kaisha | High-molecular weight derivatives of camptothecins |
| EP1695991B1 (en) | 2003-12-10 | 2010-02-17 | TOUDAI TLO, Ltd. | Coordination complex of diaminocyclohexaneplatinum(ii) with block copolymer containing poly(carboxylic acid) segment and antitumor agent comprising the same |
| JP2006248978A (ja) | 2005-03-10 | 2006-09-21 | Mebiopharm Co Ltd | 新規なリポソーム製剤 |
| EP2305275B1 (en) | 2008-06-24 | 2013-07-10 | NanoCarrier Co., Ltd. | Liquid composition comprising cisplatin-coordinating compound |
| JP2011105792A (ja) | 2009-11-12 | 2011-06-02 | Japan Science & Technology Agency | ブロックコポリマー、ブロックコポリマー−金属錯体複合体、及びそれを用いた中空構造体キャリア |
| FR2954321A1 (fr) | 2010-07-15 | 2011-06-24 | Sanofi Aventis | Derives de platine (iv) - couples a un agent de ciblage antitumoral |
| EP2754682B1 (en) | 2011-09-11 | 2017-06-07 | Nippon Kayaku Kabushiki Kaisha | Method for manufacturing block copolymer |
| US9556214B2 (en) | 2012-12-19 | 2017-01-31 | Placon Therapeutics, Inc. | Compounds, compositions, and methods for the treatment of cancers |
| JP6725520B2 (ja) * | 2015-09-14 | 2020-07-22 | 日本化薬株式会社 | ６配位白金錯体の高分子結合体 |
-
2016
- 2016-06-16 RU RU2017140223A patent/RU2695357C1/ru active
- 2016-06-16 US US15/579,754 patent/US10988496B2/en active Active
- 2016-06-16 CA CA2990369A patent/CA2990369A1/en not_active Abandoned
- 2016-06-16 CN CN201680035654.5A patent/CN107709286B/zh not_active Expired - Fee Related
- 2016-06-16 JP JP2017525288A patent/JP6797116B2/ja active Active
- 2016-06-16 AU AU2016284156A patent/AU2016284156B2/en not_active Ceased
- 2016-06-16 KR KR1020177034814A patent/KR20180019536A/ko not_active Application Discontinuation
- 2016-06-16 EP EP16814252.9A patent/EP3315487B1/en active Active
- 2016-06-16 WO PCT/JP2016/067903 patent/WO2016208481A1/ja active Application Filing
- 2016-06-22 TW TW105119624A patent/TWI703151B/zh not_active IP Right Cessation
Also Published As
| Publication number | Publication date |
|---|---|
| CN107709286A (zh) | 2018-02-16 |
| TWI703151B (zh) | 2020-09-01 |
| CA2990369A1 (en) | 2016-12-29 |
| AU2016284156A1 (en) | 2017-12-21 |
| JP6797116B2 (ja) | 2020-12-09 |
| US20180179239A1 (en) | 2018-06-28 |
| RU2695357C1 (ru) | 2019-07-23 |
| WO2016208481A1 (ja) | 2016-12-29 |
| US10988496B2 (en) | 2021-04-27 |
| EP3315487A1 (en) | 2018-05-02 |
| EP3315487B1 (en) | 2020-10-28 |
| EP3315487A4 (en) | 2019-03-13 |
| AU2016284156B2 (en) | 2020-01-30 |
| JPWO2016208481A1 (ja) | 2018-05-17 |
| CN107709286B (zh) | 2021-02-19 |
| TW201713675A (zh) | 2017-04-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Chen et al. | Novel NHC-coordinated ruthenium (II) arene complexes achieve synergistic efficacy as safe and effective anticancer therapeutics | |
| Nkoana et al. | Heterometallic half-sandwich complexes containing a ferrocenyl motif: Synthesis, molecular structure, electrochemistry and antiplasmodial evaluation | |
| Baul et al. | New dibutyltin (iv) ladders: Syntheses, structures and, optimization and evaluation of cytotoxic potential employing a375 (melanoma) and hct116 (colon carcinoma) cell lines in vitro | |
| Cerrada et al. | Gold and platinum alkynyl complexes for biomedical applications | |
| Sahu et al. | LVVO-Ethyl Maltol-Based Metallodrugs (L2–= Tridentate ONO Ligands): Hydrophobicity, Hydrolytic Stability, and Cytotoxicity via ROS-Mediated Apoptosis | |
| KR20180019536A (ko) | 신규한 백금(ⅳ) 착물 | |
| US6008395A (en) | Platinum (IV) complex, production process thereof and carcinostatic agent containing the same | |
| CN102942594A (zh) | 抗癌药用阿司匹林铂配合物及其制备方法 | |
| Zhao et al. | Synthesis, crystal structures and cytotoxicities of some transition metal complexes with N-[2-{(pyridin-2-ylmethylidene) amino} ethyl] acetamide | |
| US8895611B1 (en) | Cytotoxic compounds for treating cancer | |
| JP5179628B2 (ja) | ４価白金錯体及びそれを含む医薬組成物 | |
| CN106632322B (zh) | 一类吡唑中氮茚化合物及其制备方法与用途 | |
| WO2023246846A1 (zh) | 一种非螯合性非还原性铁死亡抑制剂及其制备方法和用途 | |
| US8367723B2 (en) | Selenoquinone-derived active organometallic complexes, methods for synthesizing same, and uses thereof | |
| Teixeira et al. | Novel family of [RuCp (N, N)(P)]+ compounds with simultaneous anticancer and antibacterial activity: Biological evaluation and solution chemistry studies | |
| EP0109677A2 (en) | Diplatinum complex, method for preparing and an anti-cancer agent containing same | |
| US11180516B2 (en) | Phosphine transition metal complex, method for producing same, and anticancer agent | |
| CN106674174A (zh) | 一种4,6‑二芳基吡喃衍生物及其在制备肝癌药物中的应用 | |
| AU2016101491A4 (en) | Cobalt-polypyridyl complex for treatment of cancer, a pharmaceutical composition and a kit comprising it | |
| ES2257178B1 (es) | Compuestos de platino de formula trans-(ptc12(isopropilamina)(4-(hidroximetil)-piridina)) y trans-(ptc12(isopropilamina)(3-hidroximetil)-piridina y su aplicacion como farmaco antitumoral. | |
| WO2022217255A1 (en) | Novel antitumor compounds and related methods of manufacture and use | |
| CN106946946A (zh) | 一种铂类抗肿瘤药物米铂氧化物的制备方法 | |
| CN103772262B (zh) | 一种具有抗肿瘤活性的异邻苯二甲酰亚胺类化合物及其应用 | |
| TW201425278A (zh) | 四價鉑錯合物及包含其之醫藥組成物 | |
| JPH07138274A (ja) | Ｚ軸上に脂溶性基を有する抗腫瘍性シクロヘキサンジアミン誘導体白金（ｉｖ）錯体 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A201 | Request for examination | ||
| E902 | Notification of reason for refusal | ||
| E601 | Decision to refuse application |